Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05931302
Other study ID # 2023-CHITS-006
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2023
Est. completion date April 2026

Study information

Verified date March 2024
Source Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Contact Florent Hugonnet, MD
Phone 07 97 98 96 59
Email florent.hugonnet@chpg.mc
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour. Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET.


Description:

Research hypothesis : Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET. Participants with lobular breast carcinoma will then undergo 18F-FDG and 68Ga-FAPI-46 PET scan. Primary objective of the study is to compare the sensitivity of 68Ga-FAPI-46 with the sensitivity of 18F-FDG in the detection of lobular breast carcinoma lesions, measured by positron emission tomography (PET). These results will be compared with the histological data collected before or during surgery (conventional histological data and immunohistochemical labeling of FAPα on the sample obtained), clinical follow-up and any results of additional examinations carried out within the usual clinical follow-up of the patients. Comparison of primary tumor and metastases uptake of 68Ga-FAPI-46 with the uptake of 18F-FDG, radiomic study of 68Ga-FAPI-46 PET and comparative radiomic study of 68Ga-FAPI-46 PET and 18F-FDG PET and comparison of the specificity of 68Ga-FAPI-46 with the specificity of 18F-FDG after a 12-month follow-up will also be performed as secondary objectives.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age greater than or equal to 18 years - ECOG from 0 to 2 - Histological diagnosis of Lobular Carcinoma of the breast based on a breast biopsy - Patient naïve to any treatment for lobular breast carcinoma - Women of childbearing age should have an adequate method of contraception - Patient having voluntarily accepted to participate in the study and signed the informed consent - Minimum tumor stage IIA - Sufficient histological material in the biopsy or the surgical specimen, if the biopsy is insufficient Exclusion Criteria: - PET scan contraindications: severe claustrophobia, unbalanced diabetes during 18F-FDG PET scans (fasting capillary blood sugar = 11 mmol) - Hormone therapy started - 18F-FDG PET scan > 21 days - Pregnant women, parturients and nursing mothers - Persons deprived of liberty by a judicial or administrative decision - Persons admitted to a health or social establishment for purposes other than research - Adults who are the subject of a legal protection measure or who are unable to express their consent

Study Design


Intervention

Diagnostic Test:
68Ga-FAPI-46 PET scan
68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients. 68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46.

Locations

Country Name City State
Monaco Centre Hospitalier Princesse Grace Monaco

Sponsors (3)

Lead Sponsor Collaborator
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer Centre Antoine Lacassagne, Institut Curie

Country where clinical trial is conducted

Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of positive tumor lesions, i.e. confirmed by additional imaging, histopathology/biopsy or response to treatment (on imaging or clinical assessment) Number of positive tumor lesions of 68Ga-FAPI-46 PET scan in comparison with 18F-FDG PET scan Up to 12 months
Secondary SUVmaxFAPI and SUVmaxFDG for each target (Standardized Uptake Value) Comparison of 68Ga-FAPI-46 and 18F-FDG Standardized Uptake Value in the primary tumor and possible metastases Up to 21 days
Secondary SUVmaxFAPI/reference and SUVmaxFDG/reference activity ratios Comparison of (SUVmaxFAPI/reference) and (SUVmaxFDG/reference) activity ratios. For the primary tumour, the reference activity will be measured in either the periphery of the lesion or on a homologous healthy tissue. For a vertebral metastasis, the reference activity will be measured in an adjacent healthy vertebra. Up to 21 days
Secondary MTVFAPI and MTVFDG (Metabolic Tumor Volume) Comparison of MTVFAPI and MTVFDG in the primary tumor and possible metastases Up to 21 days
Secondary Number of discrepancies between FAPI and FDG PET scans Discrepancies (discordant pairs) between 68Ga-FAPI-46 PET scan and 18F-FDG PET scan will be analyzed Up to 21 days
Secondary Correlation between PET scan and FAPa labeling Correlation between PET scan results and measurement of the FAPa labeling density on the biopsy Up to 12 months
Secondary Correlation between PET scan and breast histology Correlation between PET scans results and standard measurements in breast histology: OR (estrogen receptors), PR (progesterone receptors), HER2 (Human Epidermal Growth Factor Receptor-2), Ki-67 antigen, Ecadherin Up to 12 months
Secondary Specificity comparison Specificity of 68Ga-FAPI-46 PET scan will be compared to 18F-FDG PET scan specificity 12 months
Secondary Correlation between tumor lesion radiomics and histological characteristics 1st order characteristics reflecting the distribution of gray levels determined by radiomics study of 68Ga-FAPI PET scan and 18F-FDG PET scan 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05982496 - 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer N/A
Active, not recruiting NCT03620643 - Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Phase 2
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Recruiting NCT05410951 - LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Active, not recruiting NCT03414970 - Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Phase 3
Recruiting NCT05837767 - A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue N/A
Active, not recruiting NCT01038258 - Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy N/A
Completed NCT03834532 - Living Well After Breast Surgery N/A
Recruiting NCT05964504 - Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Active, not recruiting NCT04206891 - CDH1 Germline Mutations in Lobular Breast Cancer
Recruiting NCT06067503 - Biomarkers to Detect Endocrine Therapy Resistance Phase 2